# Study of Nalbuphine ER in Participants With Hepatic Impairment

> **NCT04020016** · PHASE1 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 28 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Nalbuphine ER

## Key facts

- **NCT ID:** NCT04020016
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-02-05
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04020016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04020016, "Study of Nalbuphine ER in Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04020016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*